Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2016, Article ID 9345467, 4 pages
http://dx.doi.org/10.1155/2016/9345467
Clinical Study

Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study

1Infectious Diseases Unit, University Hospital R. Poincaré, APHP, Versailles Saint Quentin University, Garches, France
2Pharmacy Department, University Hospital R. Poincaré, APHP, Versailles Saint Quentin University, Garches, France
3Infectious Diseases Unit, University Hospital of Bretonneau, Denis Diderot University, Tours, France
4Rheumatology Department, University Hospital of Bretonneau, Denis Diderot University, Tours, France

Received 19 August 2016; Revised 22 September 2016; Accepted 26 September 2016

Academic Editor: Bruce M. Rothschild

Copyright © 2016 Aurélien Dinh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Pyogenic vertebral osteomyelitis (PVO) are frequently misdiagnosed and patients often receive anti-inflammatory drugs for their back pain. We studied the impact of these medications. Methods. We performed a prospective study enrolling patients with PVO and categorized them depending on their drugs intake. Then, we compared diagnosis delay, clinical presentation at hospitalization, incidence of complications, and cure rate. Results. In total, 79 patients were included. Multivariate analysis found no correlation between anti-inflammatory drug intake and diagnosis delay, clinical presentation, complications, or outcome. Conclusion. Anti-inflammatory drugs intake does not affect diagnostic delay, severity at diagnosis, or complications of PVO.